RU2765027C2 - Способ полиалкоксилирования нуклеиновых кислот, который позволяет извлекать и повторно использовать избыток полиалкоксилирующего реагента - Google Patents

Способ полиалкоксилирования нуклеиновых кислот, который позволяет извлекать и повторно использовать избыток полиалкоксилирующего реагента Download PDF

Info

Publication number
RU2765027C2
RU2765027C2 RU2019120021A RU2019120021A RU2765027C2 RU 2765027 C2 RU2765027 C2 RU 2765027C2 RU 2019120021 A RU2019120021 A RU 2019120021A RU 2019120021 A RU2019120021 A RU 2019120021A RU 2765027 C2 RU2765027 C2 RU 2765027C2
Authority
RU
Russia
Prior art keywords
amino
paragraphs
nucleic acid
water
modified
Prior art date
Application number
RU2019120021A
Other languages
English (en)
Russian (ru)
Other versions
RU2019120021A3 (enExample
RU2019120021A (ru
Inventor
Лукас БЕТГЕ
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2019120021A publication Critical patent/RU2019120021A/ru
Publication of RU2019120021A3 publication Critical patent/RU2019120021A3/ru
Application granted granted Critical
Publication of RU2765027C2 publication Critical patent/RU2765027C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RU2019120021A 2016-11-30 2017-11-30 Способ полиалкоксилирования нуклеиновых кислот, который позволяет извлекать и повторно использовать избыток полиалкоксилирующего реагента RU2765027C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16201391.6 2016-11-30
EP16201391 2016-11-30
PCT/EP2017/001399 WO2018099600A1 (en) 2016-11-30 2017-11-30 A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent

Publications (3)

Publication Number Publication Date
RU2019120021A RU2019120021A (ru) 2021-01-11
RU2019120021A3 RU2019120021A3 (enExample) 2021-04-06
RU2765027C2 true RU2765027C2 (ru) 2022-01-24

Family

ID=57544196

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019120021A RU2765027C2 (ru) 2016-11-30 2017-11-30 Способ полиалкоксилирования нуклеиновых кислот, который позволяет извлекать и повторно использовать избыток полиалкоксилирующего реагента

Country Status (14)

Country Link
US (1) US11459352B2 (enExample)
EP (1) EP3548089B1 (enExample)
JP (1) JP7113825B2 (enExample)
KR (1) KR102611562B1 (enExample)
CN (1) CN110121363B (enExample)
AU (1) AU2017369207C1 (enExample)
BR (1) BR112019009373A8 (enExample)
CA (1) CA3043478C (enExample)
DE (1) DE17829597T1 (enExample)
ES (1) ES2975373T3 (enExample)
MX (1) MX2019006363A (enExample)
RU (1) RU2765027C2 (enExample)
SG (1) SG10202105648XA (enExample)
WO (1) WO2018099600A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201171325A1 (ru) * 2009-04-30 2012-05-30 Ноксон Фарма Аг Нуклеиновые кислоты, связывающиеся с гепсидином
WO2012149198A2 (en) * 2011-04-26 2012-11-01 Regado Biosciences, Inc. A method for manufacturing pegylated oligonucleotides
WO2015113776A1 (en) * 2014-02-03 2015-08-06 Noxxon Pharma Ag Methods for the preparation of a polyalkoxylated nucleic acid molecule

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4657919B2 (ja) * 2002-08-19 2011-03-23 プレジデント アンド フェローズ オブ ハーバード カレッジ 進化する新しい分子機能
JP4698579B2 (ja) * 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
WO2005042563A2 (en) * 2003-10-22 2005-05-12 Akzo Nobel N.V. Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
CA2607185A1 (en) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents
US9388457B2 (en) * 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
DE102007058713A1 (de) * 2007-12-06 2009-06-10 Evonik Goldschmidt Gmbh Silicon(meth-)acrylat-Partikel, Verfahren zu deren Herstellung sowie deren Verwendung
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
JP2014533098A (ja) 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
SG11201405552VA (en) * 2012-03-16 2014-10-30 Merck Patent Gmbh Targeting aminoacid lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201171325A1 (ru) * 2009-04-30 2012-05-30 Ноксон Фарма Аг Нуклеиновые кислоты, связывающиеся с гепсидином
WO2012149198A2 (en) * 2011-04-26 2012-11-01 Regado Biosciences, Inc. A method for manufacturing pegylated oligonucleotides
WO2015113776A1 (en) * 2014-02-03 2015-08-06 Noxxon Pharma Ag Methods for the preparation of a polyalkoxylated nucleic acid molecule

Also Published As

Publication number Publication date
CN110121363B (zh) 2023-08-29
BR112019009373A8 (pt) 2023-04-11
KR102611562B1 (ko) 2023-12-07
MX2019006363A (es) 2019-11-12
WO2018099600A1 (en) 2018-06-07
SG10202105648XA (en) 2021-06-29
AU2017369207A1 (en) 2019-05-23
AU2017369207C1 (en) 2024-06-27
CN110121363A (zh) 2019-08-13
EP3548089A1 (en) 2019-10-09
AU2017369207A9 (en) 2019-07-25
US20200291057A1 (en) 2020-09-17
RU2019120021A3 (enExample) 2021-04-06
CA3043478C (en) 2023-07-25
JP7113825B2 (ja) 2022-08-05
CA3043478A1 (en) 2018-06-07
US11459352B2 (en) 2022-10-04
WO2018099600A9 (en) 2023-12-28
WO2018099600A8 (en) 2019-07-04
DE17829597T1 (de) 2019-12-05
RU2019120021A (ru) 2021-01-11
KR20190088062A (ko) 2019-07-25
AU2017369207B2 (en) 2023-12-14
EP3548089C0 (en) 2023-12-27
EP3548089B1 (en) 2023-12-27
BR112019009373A2 (enExample) 2019-07-23
JP2020500519A (ja) 2020-01-16
ES2975373T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
CN106279300B (zh) Rig-i配体及其生产方法
KR101189555B1 (ko) 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법
KR20190115445A (ko) 감소된 신장 청소율을 갖는 다중결합 올리고뉴클레오티드
WO2021026490A1 (en) Cns targeting with multimeric oligonucleotides
RU2564855C2 (ru) Способ получения пэгилированных олигонуклеотидов
RU2765027C2 (ru) Способ полиалкоксилирования нуклеиновых кислот, который позволяет извлекать и повторно использовать избыток полиалкоксилирующего реагента
JP2023504186A (ja) 標的化された核酸送達のためのペプチドドッキング賦形剤
JP2021072823A (ja) ポリアルコキシル化核酸分子の調製のための方法
HK40007263B (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
HK40007263A (en) A method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent
US20100056612A1 (en) Molecular entities for binding, stabilization and cellular delivery of charged molecules
CN117482243A (zh) 一种偶联物及其用途
CN117482242A (zh) 一种偶联物及其用途
HK1255466B (en) Oligonucleotide conjugation process
WO2009073820A2 (en) Biopolymer-nucleic acid conjugation